Next Article in Journal
A Single-Tube HNB-Based Loop-Mediated Isothermal Amplification for the Robust Detection of the Ostreid herpesvirus 1
Next Article in Special Issue
Psoriasis and Antimicrobial Peptides
Previous Article in Journal
MicroRNAs Responding to Space Radiation
Previous Article in Special Issue
Oxidative Stress as an Important Contributor to the Pathogenesis of Psoriasis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 18
10.3390/ijms21186604
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Role of Innate Immune Cells in Psoriasis

by
Yuki Sato
,
Eisaku Ogawa
and
Ryuhei Okuyama
*
Department of Dermatology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(18), 6604; https://doi.org/10.3390/ijms21186604
Submission received: 19 August 2020 / Revised: 8 September 2020 / Accepted: 8 September 2020 / Published: 9 September 2020
(This article belongs to the Special Issue Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated)
Browse Figures
Review Reports Versions Notes

Abstract

:
Psoriasis is a chronic inflammatory skin condition caused by a combination of hereditary and environmental factors. Its development is closely related to the adaptive immune response. T helper 17 cells are major IL-17-producing cells, a function that plays an important role in the pathogenesis of psoriasis. However, recent findings have demonstrated that innate immune cells also contribute to the development of psoriasis. Innate lymphoid cells, γδ T cells, natural killer T cells, and natural killer cells are activated in psoriasis, contributing to disease pathology through IL-17-dependent and -independent mechanisms. The present review provides an overview of recent findings, demonstrating a role for innate immunity in psoriasis.

1. Introduction

Psoriasis is a chronic inflammatory skin disease characterized by unique skin symptoms, most commonly manifesting as erythema covered by silvery lamellar scales. Although its etiology remains incompletely understood, recent studies have revealed that pathological crosstalk between immune cells and keratinocytes, which is activated by a combination of hereditary and environmental factors, drives the development and progression of psoriasis.
In 1979, cyclosporine A was identified to be an effective psoriasis treatment [1], suggesting the involvement of T-cell immunity in psoriasis because cyclosporine A suppresses T-cell activity via the calcineurin phosphatase pathway. Subsequently, the role of CD4+ T cells in psoriasis has been intensely investigated, revealing that psoriasis-like dermatitis develops in mice transplanted with CD4+ T cells from psoriasis patients [2,3]. Furthermore, cytokines secreted by T helper 1 (Th1) cells, including interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), are increased in the psoriatic lesions and peripheral blood of psoriasis patients [4,5,6]. Therefore, Th1 cells have been the predominant focus of psoriasis research. However, administration of IFN-γ and TNF-α does not reproduce psoriasis pathology [7,8,9], suggesting that Th1 cell induction of experimental psoriasis cannot be fully explained by Th1 cytokine function.
In 1996, IL-17 was newly identified as a proinflammatory cytokine produced by human CD4+ T cells [10]. IL-17 is comprised of six subtypes, from IL-17A to IL-17F [11,12]. IL-17A, which induces cell proliferation, abnormal cell differentiation, and production of cytokines, chemokines, and antimicrobial peptides in keratinocytes, is increased in psoriatic lesions [11,12]. IL-17-producing CD4+ T cells, T helper 17 cells (Th17), were found to play a role in psoriasis [13,14]. Furthermore, IL-23 is essential to the maintenance of Th17 cells, and is abundant in psoriatic lesions [15,16,17]. The IL-23/IL-17 cascade is thought to play a major role in psoriasis, particularly because clinical outcomes of psoriasis are dramatically improved by therapies targeting IL-17 and IL-23 [18,19,20]. Th17 cells have been regarded as a major source of IL-17.
However, IL-17 is also produced by other immune cells involved in the innate immune response, including group 3 innate lymphoid cells (ILC3s), γδ T cells, natural killer (NK) cells, and natural killer T (NKT) cells [21,22]. Similar to Th17 cells that regulate adaptive immunity, these innate immune cells appear to contribute to the pathogenesis of psoriasis. In the present review, we discuss the newly identified roles of innate immune cells in psoriasis, especially ILC3s, γδ T cells, NK cells, and NKT cells.

2. Group 3 Innate Lymphoid Cells (ILC3s)

2.1. ILC3 Characteristics

ILCs are a newly identified member of the lymphoid lineage, and are key players in immunomodulated processes such as maintenance of barrier function and early response to infection in tissues that contact exogenous pathogens, such as the skin, lung, and gastrointestinal tract [23]. Unlike T cells and B cells, ILCs do not have an antigen-specific receptor [23,24]. Instead, ILCs are activated through signals from cytokine receptors and NK receptors, and rapidly produce large amounts of cytokines. Based on these characteristics, ILCs are classified as innate immune cells and are roughly divided into three types, ILC1, ILC2, and ILC3, based on cytokine production and transcription factor expression. Similar to the differential cytokine production profiles among different subtypes of effector T cells, ILC1s produce IL-12/IFN-γ, ILC2s produce IL-4/IL-5, and ILC3s produce IL-17/IL-22 [23]. The development of ILC3s requires the transcription factor RORγt. ILC3s are classified into natural cytotoxicity receptor-positive (NCR+) ILC3, NCR– ILC3, and lymphoid tissue inducer (LTi) cells [25,26]. NCR+ ILC3s produce IL-22 in response to IL-23 and IL-1β stimulation. When activated, NCR– ILC3s produce IL-17, IL-22, and IFN-γ [23]. LTi cells produce lymphotoxin in addition to IL-17 and IL-22 [26].

2.2. ILC3s Contribute to the Development of Psoriasis via IL-22

ILC3s are thought to contribute to the pathogenesis of psoriasis because some ILC3s have the ability to produce IL-17 [23]. ILC3s are distributed differentially in normal and psoriatic skin. In normal human skin, a few ILC3s are present, primarily in the upper layer of the dermis, and are absent in the epidermis [27]. While ILC3s are commonly NCR– in normal skin, NCR+ ILC3s are increased in psoriatic lesions [28,29] (Figure 1). NCR– ILC3s isolated from healthy skin convert to NCR+ ILC3s in response to IL-2, IL-23, and IL-1β stimulation in vitro [25]. NCR+ ILC3s isolated from psoriatic lesions produce high levels of IL-22, but not IL-17, under IL-2, IL-23, and IL-1β stimulation in vitro [28] (Table 1). Consistently, IL-22 is closely associated with psoriasis pathogenesis, modulating pathological events such as keratinocyte proliferation and upregulation of antimicrobial molecules such as S100A7, S100A8, and S100A9 [30]. NCR+ ILC3s increase IL-22 production by IL-1β and IL-23 secreted from keratinocytes and TNF/nitric oxide-producing dendritic cells, respectively [13,28,31] (Figure 1). Interestingly, ILC3s purified from cultured blood cells induce the formation of psoriasis-like dermatitis in a human skin xenotransplant mouse model, suggesting that ILC3s promote the development of psoriasis independent of other immune cells [32]. Further, ILC3s are located near lymphocytes, not near blood vessels or the epidermis, suggesting that cellular crosstalk between ILC3s and lymphocytes could be important in psoriasis pathogenesis [27].

2.3. Peripheral Blood ILC3s in Psoriasis Patients

It is likely that psoriasis pathogenesis involves not only skin ILC3s, but also circulating ILC3s in the peripheral blood. A few ILC3s are present in normal human peripheral blood, most of which are NCR– [28,29,33]. The proportion of NCR+ ILC3s to total ILC3s is increased in the peripheral blood of psoriasis patients [28,29], and NCR+ ILC3s from psoriasis patients are able to produce IL-22 [28]. Further, the proportion of peripheral blood NCR+ ILC3s is positively correlated with skin lesion severity, and decreases in correlation with improvement of psoriatic lesions in response to treatment with an anti-TNF-α antibody [29].

2.4. ILC3s in Psoriasis Mouse Models

The involvement of ILC3s in psoriatic pathogenesis has been evaluated using mouse models. Topical application of imiquimod, an immune response modifier, induces psoriasis-like dermatitis accompanied by hyperkeratosis, acanthosis, and inflammatory cell infiltration [34]. The administration of an IL-23 antibody, which blocks a key cytokine in psoriasis, improves imiquimod-induced dermatitis, suggesting that this model has a similar pathological mechanism to psoriasis [35]. Imiquimod does not induce psoriasis-like dermatitis in Ror−/− mice, suggesting the contribution of ILC3s, γδ T cells, and Th17 cells to imiquimod-induced psoriasis-like dermatitis [35]. Interestingly, imiquimod application induces moderate dermatitis in Rag1–/– mice, which lack αβ T cells and γδ T cells, but not ILC3s [36]. In addition, imiquimod does not induce psoriatic dermatitis in Rag2–/–/Il2rg–/– mice, which lack αβ T cells, γδ T cells, and ILCs [35]. Taken together, these findings suggest that ILC3s contribute to the development of imiquimod-induced psoriatic dermatitis.
Intradermal injection of IL-23 also induces psoriasis-like dermatitis [37]. IL-23-injected Rag1–/– mice exhibit hyperkeratosis, dilated dermal capillaries, mild acanthosis, and dermal inflammation, similar to IL-23-injected wild-type mice [38]. IL-23 injection induces dermatitis even in the absence of αβ T cells and γδ T cells.

3. γδ T Cells

3.1. Characteristics of γδ T Cells as Innate Immune Cells

γδ T cells have the properties of innate immune cells. In contrast to classical T cells (αβ T cells), in which the T-cell receptor (TCR) consists of an α and β chain, γδ T cells express TCRs containing a γ and δ chain [39]. Due to decreased numbers of gene fragments, the diversity of γδ chains is much less than that of αβ chains [39,40]. γδ T cells are primarily activated by cytokine stimulation and exhibit effector functions in the absence of TCR stimulation [41]. γδ T cells also express toll-like receptors that recognize intrinsic and extrinsic risk signals [41,42]. Based on these characteristics, which are consistent with those of innate immune cells, γδ T cells are classified as innate immune T cells.

3.2. γδ T Cells in Humans

In humans, γδ T cells are classified into Vδ1−Vδ3 by the δ chain [39]. Vδ1 cells are present in barrier tissues such as the skin, and are important in cancer immunity and wound healing [39,43,44]. In the context of cancer immunity, Vδ1 cells in the dermis produce IFN-γ, exert cytotoxic functions similar to those of CD8+ T cells [45], and infiltrate into solid tumors such as melanomas [46]. In the context of wound healing, epidermal Vδ1 secrete insulin-like growth factor 1, activating cell proliferation and secretion of other growth factors [47]. Vδ2 and Vδ3 cells are present in the peripheral blood, and Vγ9Vδ2 cells are the major population in human blood [48].

3.3. γδ T Cells in Psoriasis Patients

Dermal γδ T cells increase in psoriatic lesions compared with healthy skin, and IL-17-producing γδ T cells also increase in psoriatic lesions [49,50]. Analyses of cultured cells isolated from skin lesions have revealed that the number and proportion of IL-17-producing γδ T cells are higher than those of TCRδ T cells in psoriatic lesions [49]. This finding suggests that γδ T cells contribute to the pathogenesis of psoriasis. IL-1β is secreted by keratinocytes, dendritic cells, and macrophages [51]. Intriguingly, IL-1β expression is higher in psoriatic lesions than in healthy skin, and decreases in parallel with clinical improvement of psoriasis severity [51].
In psoriasis patients, Vγ9Vδ2+ T cells decrease in the peripheral blood and increase in psoriatic lesions [52]. Cutaneous lymphocyte antigen (CLA)-positive Vγ9Vδ2+ T cells also decrease in the peripheral blood [52]. Intriguingly, the proportion of CLA+/Vγ9Vδ2+ T cells to total Vγ9Vδ2+ γδ T cells increases in disrupted skin with suction blisters, but not in the peripheral blood [52]. CLA+ Vγ9Vδ2+ T cells could infiltrate from the peripheral blood into inflammatory lesions, such as those of psoriasis. CLA+/Vγ9Vδ2+ T cells from healthy control subjects produce IFN-γ, TNF-α, and IL-17 in response to in vitro stimulation [52]. Indeed, culture supernatant from CLA+/Vγ9Vδ2+ T cells activates keratinocytes and induces the expression of intercellular adhesion molecule 1(ICAM-1), human leukocyte antigen (HLA)-DR, IL-6, and TNF-α [52], suggesting pro-inflammatory crosstalk between CLA+/Vγ9Vδ2+ T cells and keratinocytes.
However, high-throughput screening of TCRs revealed that the proportion of γδ T cells to total T cells is less than 1% in psoriatic skin lesions [53]. The majority of IL-17-producing T-cell clones are αβ T cells, not γδ T cells. It is therefore necessary to further evaluate how γδ T cells are involved in psoriasis, and their relative role in comparison with αβ T cells.

3.4. γδ T Cells in Mice

In mice, γδ T cells account for more than 99% of CD3+ cells in the epidermis [54]. γδ T cells are classified into Vγ1−Vγ7 by γ chain, and epidermal γδ T cells are predominately Vγ5+ [54]. Epidermal γδ T cells are referred to as dendritic epidermal T cells (DETCs) due to their morphology, which is similar to that of dendritic cells (Figure 2). DETCs appear to contribute to the maintenance of skin homeostasis and wound healing [55]. On the other hand, γδ T cells account for about 50% of CD3+ cells in the murine dermis [54]. Approximately 40–50% of γδ T cells in the dermis are Vγ4+, and about 40% of γδ T cells are Vγ6+ [54,56]. Dermal γδ T cells express RORγt, IL-7R, CCR6, IL-23R, and IL-17 [49,57].

3.5. γδ T Cells Contribute to Psoriasis-Like Dermatitis in Murine Models via IL-17 Production

γδ T cells have been intensely investigated in mouse models of psoriasis. IL-17-producing γδ T cells increase in the dermis of IL-23-injected mice, which develop psoriasis-like dermatitis [49]. About 90% of IL-17-producing cells in IL-23-induced dermatitis are dermal γδ T cells [49] (Figure 2). In addition, in cultured suspensions of dermal cells stimulated with IL-23, about 90% of IL-17-producing cells are γδ T cells [49]. Together, these findings suggest that γδ T cells are the major source of IL-17 in the IL-23-induced dermatitis mouse model (Table 1).
Furthermore, IL-23 induction of psoriasis-like dermatitis is attenuated in Tcr–/– mice that lack γδ T cells, as demonstrated by a relatively modest increase in skin thickness and infiltration of inflammatory cells [49]. However, IL-23 induces psoriatic dermatitis in Tcra–/– mice similarly to wild-type mice despite αβ T-cell depletion [49]. IL-23 induction of IL-17 production is significantly lower in the skin of Tcrd–/– mice relative to wild-type and Tcra–/– mice. Taken together, these findings suggest that IL-23 induces psoriatic dermatitis in mice by inducing IL-17 secretion in γδ T cells rather than αβ T cells.
On the other hand, epidermal IL-22-producing γδ T cells increase in IL-23-induced psoriasis-like dermatitis [58]. These γδ T cells express chemokine receptor 6 (CCR6) and do not express Vγ5 (Figure 2). CCR6+ γδ T cells could migrate from the dermis to the epidermis to modulate psoriatic dermatitis via IL-22 secretion because Vγ5- cells are rarely present in the normal epidermis.
Similarly, dermal γδ T cells and expression of IL-23 and IL-17 are increased in imiquimod-induced psoriasis-like dermatitis [49]. In this context, IL-23 is primarily secreted by dendritic cells and macrophages. IL-17-producing Vγ4 cells are increased in imiquimod-treated mice, suggesting the contribution of dermal γδ T cells, especially Vγ4 cells, to imiquimod-induced psoriasis-like dermatitis [56] (Figure 2). In addition, imiquimod treatment does not significantly induce psoriatic dermatitis, as indicated by lack of epidermal thickening and inflammatory infiltration, in Tcrd–/– mice that lack γδ T cells [49]. Taken together, these findings demonstrate that γδ T cells are essential for the induction of psoriatic dermatitis in imiquimod and IL-23 mouse models.

3.6. IL-1β Signaling Is Essential for γδ T-Cell Induction of Psoriasis

While IL-17 production is induced by IL-23 in dermal γδ T cells, IL-17 is more strongly induced by co-stimulation with IL-1β and IL-23 [56] (Figure 2). Consistently, injection of an anti-IL-1β antibody suppresses IL-17 production in γδ T cells of an IL-23 mouse model. Moreover, IL-17 secretion is not induced by IL-23 stimulation of dermal γδ T cells from Il1–/– mice in vitro [56]. These findings suggest that IL-1β signaling is essential for γδ T-cell activation and IL-17 production, which is supported by the finding that IL-1β expression is elevated in imiquimod-treated skin [51]. Imiquimod-induced dermatitis is attenuated in Il1r–/– mice, as is induction of IL-17 and IL-22 secretion [56]. In addition, in chimeric mice in which Il1r is deficient only in γδ T cells, imiquimod treatment does not induce skin acanthosis or expression of IL-17 and TNF-α [51]. On the other hand, IL-22 expression in chimeric mice is comparable to that of wild-type mice [51]. The findings suggest that IL-1β signaling is essential for IL-17 production in dermal γδ T cells in the context of imiquimod-induced psoriatic dermatitis.
Relative to specific pathogen-free mice, germ-free mice exhibit decreased IL-1β, decreased total dermal γδ T cells, and decreased IL-17-producing γδ T cells [51]. IL-23 stimulation of IL-17 production is also decreased in γδ T cells from germ-free mice. This suggests that skin commensal organisms contribute to γδ T-cell activation. Skin commensal organisms are altered in psoriasis [51] and may contribute to the development of psoriasis by regulating γδ T-cell function via IL-1β.

3.7. Memory Cell-Like Function of γδ T Cells in Psoriasis

It is likely that γδ T cells have memory cell-like immune function. In the imiquimod model of psoriasis-like dermatitis, imiquimod activates IL-17-producing Vγ4+ T cells, inducing the migration of γδ T cells to lymph nodes and subsequent proliferation and long-term survival of γδ T cells [50]. Moreover, a second application of imiquimod results in severe skin inflammation through migration of γδ T cells to the treated area [50]. γδ T cells could possess immunological memory, which could contribute to rapid psoriasis relapse following external imiquimod re-application to psoriasis lesions [59].

4. NKT Cells

4.1. NKT Cell Characteristics

NKT cells express not only the NK receptor, but also a TCR, which consists of α and β chains. Similar to NK cells, NKT cells ordinarily express CD161 receptor (also known as NK1.1) and the NKG2/CD94 heterodimer (Figure 3). NKT cells are classified into type I and type II according to the TCR type [60]. Type I cells are also known as invariant NKT (iNKT) cells, as these cells use only the single Vα domain of the TCR α chain (mouse, Vα14Jα18; human, Vα24Jα18) and a few Vβ domains of the TCR β chain (mouse, Vβ8.2, β7 or β2; human, Vβ11) [60,61]. This TCR recognizes lipids and glycolipids presented on CD1d, a non-classical major histocompatibility complex class I (MHC-I) in mice [61,62]. Type II NKT cells express other TCR types.
NKT cells rapidly produce large amounts of cytokines in response to various stimuli such as lipids, cytokines, and cellular stressors [61]. Mouse iNKT cells are classified into three types according to cytokine production: NKT1 cells that express T-box transcription factor 21 (T-bet) and produce IFN-γ, NKT2 cells that express promyelocytic leukemia zinc finger (PLZF) and produce IL-4, and NKT17 cells that express RORγt and produce IL-17 [61,63,64] (Figure 3). However, whether human NKT cells can be classified according to cytokine production remains unclear.

4.2. NKT Cells in Psoriatic Lesions

NKT cells are found in psoriatic skin lesions [65] and decrease after treatment [66,67]. Furthermore, iNKT cells, specifically Vα24+/CD161+ iNKT cells, increase in the blood of psoriasis patients [68]. By contrast, other groups have reported decreased Vα24+/Vβ11+ iNKT cells in the blood of psoriasis patients [69]. Hence, there is no current consensus regarding the change of circulating NKT cells in psoriasis. However, psoriatic dermatitis is induced by transplantation of immune cells from the peripheral blood of psoriasis patients into SCID mice with human skin xenografts, and a proportion of the infiltrating cells express NK receptors [70]. Moreover, psoriatic dermatitis is induced by transplantation of NK receptor-positive cells, including NK cells and NKT cells [71]. Thus, it is likely that NK cells and/or NKT cells contribute to the pathogenesis of psoriasis.

4.3. Co-Activation of NKT Cells and Keratinocytes

The association between CD161 expressed on NKT cells and CD1d expressed on keratinocytes in psoriasis has been intensely investigated. In healthy skin, CD1d is expressed only on keratinocytes in the outermost three or four cell layers, extending from the granular layer up to the lipid-rich stratum corneum [65]. On the other hand, in the psoriatic epidermis, CD1d is diffusely expressed on keratinocytes from the basal layer to the outer spinous layer beneath the parakeratotic layers [65]. Interestingly, IFN-γ treatment induces keratinocyte expression of CD1d in vitro [65]. Furthermore, in co-culture with CD1d+ keratinocytes pre-treated with IFN-γ, CD94+/CD161+ NKT cells from psoriasis patients produce large amounts of IFN-γ, which is suppressed by an anti-CD1d antibody [72] (Table 1). This finding suggests that NKT cells produce large quantities of INF-γ by interacting with keratinocyte CD1d, which is in turn upregulated by IFN-γ (Figure 3). NKT cells and keratinocytes may therefore form a positive feedback cell activation loop via IFN-γ.

4.4. NKT Cells and IL-17

IL-17 is involved in psoriasis pathology and is produced by some NKT cells, which are termed NKT17 cells [73]. NKT17 cells produce IL-17 in response to stimulation with IL-1β and IL-23 [74] and are present in the lung, liver, marginal lymph nodes, and skin [75] (Figure 3). However, the role of NKT17 cells has not yet been defined in the skin [76,77], and the role of NKT17 cells in psoriasis therefore remains unclear.
Interestingly, mouse studies have demonstrated that CD1-autoreactive T cells contribute to the development of psoriatic dermatitis in hyperlipidemia [78]. The CD1-autoreactive TCR binds to CD1b on dendritic cells, which induces IL-17 production in CD1-autoreactive T cells (Figure 3). CD1 autoreactive T cells are similar to NKT17 cells in terms of IL-17 production in response to invariant TCRs and lipids. Therefore, CD1-autoreactive T cells could also be a source of IL-17 in psoriasis.

5. NK Cells

5.1. NK Cell Characteristics

NK cells possess both effector and cytotoxic functions, and distinguish infected cells and cancer cells from normal cells using NK receptors [79]. Their effector function is exerted by release of pro-inflammatory cytokines such as IFN-γ [80]. Furthermore, NK cells exert cytotoxicity via secreting perforin, granzymes, and granulysin (GNLY), and induce apoptosis via the Fas ligand [80,81,82]. NK receptors are classified into activating and inhibitory receptors by their effect on NK cell function [83], and NK cells are regulated by the integration of signals from both activating and inhibitory receptors.
According to structure, NK receptors are classified as killer cell immunoglobulin-like receptors (KIRs) and C-type lectin-like receptors (CTLRs) [84,85]. KIRs are classified into inhibitory and activating receptors [83]. Inhibitory KIRs, such as KIR3DL1, generally have long cytoplasmic tails with immunoreceptor tyrosine-based inhibitory motifs. Contrastingly, activating receptors, such as KIR3DS1, generally have short cytoplasmic tails with immunoreceptor tyrosine-based activating motifs [83,86]. CTLRs are also divided into activating and inhibitory types: NKG2A is an inhibitory type; NKG2C, NKG2E, NKG2D, and NKG2F are activating types [85,87].
Many of the genes for NK receptor ligands are encoded in the MHC region. Classical MHC-I receptors, such as HLA-A, -B, and -C in humans, are recognized by KIRs [84]. Among CTLRs, NKG2A and NKG2C bind HLA-E (a non-classical MHC-I), and NKG2D binds MHC class I-related chain (MIC)-A/B (a non-classical MHC-I) and Retinoic acid early transcript (RAET) family receptors, which have homology to MHC-I [81,84,87].
NK cells are roughly divided into two subtypes according to the intensity of CD56 expression [79]. CD56dim NK cells are the major component of NK cells in the peripheral blood, accounting for over 90% of all peripheral blood NK cells, and are therefore referred to as circulating NK cells [88]. CD56dim NK cells express inhibitory receptors such as KIRs, and cytotoxic proteins such as perforin and granzyme B [88]. Contrastingly, CD56bright NK cells are primarily present in peripheral tissues, including the skin, and are a minor component of the peripheral blood [88]. CD56bright NK cells are therefore referred to as tissue-resident NK cells [89]. CD56bright NK cells express NKG2A/CD94 rather than KIRs and cytotoxic proteins, and are capable of producing IFN-γ, TNF-α, and granulocyte macrophage colony-stimulating factor (GM-CSF) [89,90,91].

5.2. Effector Function of NK Cells in Psoriatic Lesions

Although the roles of NK cells in psoriasis have been investigated, their contribution to disease development and progression remains incompletely understood. NK cells are increased in psoriatic skin lesions [92,93,94]. CD56+/CD3− NK cells account for 5–8% of all infiltrating cells in psoriatic lesions, are comprised primarily of CD56bright NK cells that express the inhibitory receptor NKG2A, and are therefore considered as tissue-resident NK cells [94]. In addition, NK cells isolated from psoriatic lesions express the activation marker CD69, and IL-2 stimulation induces the production of IFN-γ and TNF-α in vitro [94] (Table 1). It is likely that NK cells in psoriatic lesions have effector rather than cytotoxic functions. Moreover, treatment of cultured keratinocytes with media supernatant from activated CD56+/CD3− NK cells isolated from psoriatic lesions induces keratinocyte expression of ICAM-1, HLA-DR, C-X-C motif chemokine ligand 10 (CXCL10), C-C motif chemokine ligand 5 (CCL5), and C-C motif chemokine ligand 20 (CCL20), suggesting that NK cell stimulation of keratinocytes leads to intra-epidermal infiltration of inflammatory cells via induction of adhesion molecules and chemokine expression in keratinocytes [94]. In psoriatic lesions, NK cell-induced inflammation may be based on keratinocyte activation via cytokines such as IFN-γ and TNF-α (Figure 4).
Intriguingly, HLA-G, a non-classical MHC-I, is expressed in the psoriatic epidermis, but not in the healthy epidermis [95]. HLA-G is a ligand for KIR2DL4, an activating NK cell receptor; hence, NK cells may be activated by HLA-G expressed on keratinocytes in psoriatic lesions [95,96] (Figure 4).
IL-17, IL-22, and IL-23 are known to play important roles in the pathogenesis of psoriasis, and NK cells could produce both IL-17 and IL-22. IL-17-producing NK cells increase in the synovial fluid of undifferentiated spondyloarthritis patients, a disease closely related to psoriatic arthritis [97]. IL-22-producing NK cells, also referred to as NK-22 cells [98], are present in mucosa-associated lymphoid tissues, such as the tonsils and Peyer’s patches. At this time, the roles of IL-17-producing NK cells and NK-22 cells have not been investigated in psoriasis, and their roles in this context remains to be elucidated, although their pathogenic roles in related diseases are suggestive of a role in psoriasis.

5.3. Effector Function of Peripheral Blood NK Cells in Psoriasis Patients

It is not clear whether peripheral blood NK cells contribute to the pathogenesis of psoriasis. The number of peripheral blood NK cells is reduced in psoriasis patients [99,100]. Furthermore, the levels of inflammatory cytokines, including IFN-γ and TNF-α, do not differ between peripheral blood NK cells from psoriasis patients and healthy controls [101]. In addition, in vitro stimulation of IFN-γ and TNF-α production is decreased in NK cells from psoriasis patients relative to NK cells from healthy controls [101].

5.4. Cytotoxic Function of NK Cells in Psoriasis

The frequency of GNLY+ NK cells is increased in the peripheral blood of psoriasis patients. Similarly, the frequency of psoriatic lesion GNLY+ NK cells is increased relative to healthy controls and healthy non-psoriatic skin [102]. Interestingly, genetic analyses suggest a relationship between GNLY polymorphisms and psoriasis [103]. On the other hand, a seemingly contrasting report suggested that the expression of Fas ligand in NK cells isolated from the peripheral blood does not differ between psoriasis patients and healthy control subjects [101]. Further studies are expected to resolve these discrepancies.

5.5. Genetic Analyses of HLA and KIR in Psoriasis

Polymorphisms in HLA genes are associated with psoriasis susceptibility [104,105,106]. The frequencies of HLA-Cw*0602 and KIR2DS1 are higher in psoriasis patients than in healthy control subjects [104]. NK cells recognize some types of HLA-C receptors through the activating receptor KIR2DS1 or the inhibitory receptor KIR2DL1 [107]. Furthermore, the frequencies of HLA-B Bw4-80I and KIR3DS1 polymorphisms are higher in psoriasis patients than in healthy control subjects [105]. NK cells recognize HLA-Bw4 through the activating receptor KIR3DS1 or the inhibitory receptor KIR3DL1 [107]. In addition, the frequencies of the HLA-E*01:01 allele and deletion of NKG2C, an activating NK receptor, are also higher in psoriasis patients [106]. Thus, similar to HLA, polymorphisms in activating and inhibitory receptors of NK cells are associated with susceptibility to psoriasis, which may be affected by activation of NK cells through the binding of activating/inhibitory receptors with HLA.

5.6. NK Cells in Mouse Models of Psoriasis

In the imiquimod-induced psoriasis-like dermatitis mouse model, NK cells are decreased in the peripheral blood and spleen [108]. However, the role of NK cells in psoriasis mouse models remains unclear, although NK cell maturation markers, such as CD11b, CD43, CD27, and killer cell lectin-like receptor G1 (KLRG1), increase in peripheral blood and spleen NK cells from imiquimod-treated mice [109]. Furthermore, alterations in maturation marker expression are correlated with disease severity [109].

6. Conclusions

It is likely that ILC3s, γδ T cells, NKT cells, and NK cells are associated with psoriasis pathogenesis. These cell types are frequently increased in psoriasis lesions. Furthermore, decreased induction of psoriasis in mouse models that lack these cell types and induction of psoriasis by transplantation of these cell types into mouse models indicate that these cells are involved in the development of psoriasis. In addition, peripheral blood NCR+ ILC3s decrease after treatment [29], suggesting that these cells are markers of psoriasis severity.

Author Contributions

All authors have equally contributed to the writing and editing of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mueller, W.; Herrmann, B. Cyclosporin A for psoriasis. N. Engl. J. Med. 1979, 301, 555. [Google Scholar] [CrossRef] [PubMed]
  2. Wrone-Smith, T.; Nickoloff, B.J. Dermal injection of immunocytes induces psoriasis. J. Clin. Investig. 1996, 98, 1878–1887. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Boyman, O.; Hefti, H.P.; Conrad, C.; Nickoloff, B.J.; Suter, M.; Nestle, F.O. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 2004, 199, 731–736. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Nestle, F.O.; Turka, L.A.; Nickoloff, B.J. Characterization of dermal dendritic cells in psoriasis: Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Investig. 1994, 94, 202–209. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Schlaak, J.F.; Buslau, M.; Jochum, W.; Hermann, E.; Girndt, M.; Gallati, H.; Meyer zum Büschenfelde, K.H.; Fleischer, B. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Investig. Dermatol. 1994, 102, 145–149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Austin, L.M.; Ozawa, M.; Kikuchi, T.; Walters, I.B.; Krueger, J.G. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is al. J. Investig. Dermatol. 1999, 113, 752–759. [Google Scholar] [CrossRef] [Green Version]
  7. Hancock, G.; Kaplan, G.; Cohn, Z. Keratinocyte growth regulation by the products of the immune cells. J. Exp. Med. 1988, 168, 1395–1402. [Google Scholar] [CrossRef]
  8. Detmar, M.; Orfanos, C.E. Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro. Arch. Dermatol. Res. 1990, 282, 238–245. [Google Scholar] [CrossRef]
  9. Krueger, G.; Callis, K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol. 2004, 140, 218–225. [Google Scholar] [CrossRef]
  10. Fossiez, F. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 1996, 183, 2593–2603. [Google Scholar] [CrossRef] [Green Version]
  11. Iwakura, Y.; Ishigame, H.; Saijo, S.; Nakae, S. Functional Specialization of Interleukin-17 Family Members. Immunity 2011, 34, 149–162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Di Cesare, A.; Di Meglio, P.; Nestle, F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Investig. Dermatol. 2009, 129, 1339–1350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Lowes, M.A.; Kikuchi, T.; Fuentes-Duculan, J.; Cardinale, I.; Zaba, L.C.; Haider, A.S.; Bowman, E.P.; Krueger, J.G. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Investig. Dermatol. 2008, 128, 1207–1211. [Google Scholar] [CrossRef] [PubMed]
  14. Fitch, E.; Harper, E.; Skorcheva, I.; Kurtz, S.E.; Blauvelt, A. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr. Rheumatol. Rep. 2007, 9, 461–467. [Google Scholar] [CrossRef] [Green Version]
  15. Kastelein, R.A.; Hunter, C.A.; Cua, D.J. Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 2007, 25, 221–242. [Google Scholar] [CrossRef] [Green Version]
  16. Stockinger, B.; Veldhoen, M. Differentiation and function of Th17 T cells. Curr. Opin. Immunol. 2007, 19, 281–286. [Google Scholar] [CrossRef]
  17. Piskin, G.; Sylva-Steenland, R.M.R.; Bos, J.D.; Teunissen, M.B.M. In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin. J. Immunol. 2006, 176, 1908–1915. [Google Scholar] [CrossRef]
  18. Amin, M.; Darji, K.; No, D.J.; Wu, J.J. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 1627–1632. [Google Scholar] [CrossRef]
  19. Griffiths, C.E.M.; Reich, K.; Lebwohl, M.; van de Kerkhof, P.; Paul, C.; Menter, A.; Cameron, G.S.; Erickson, J.; Zhang, L.; Secrest, R.J.; et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet (Lond. Engl.) 2015, 386, 541–551. [Google Scholar] [CrossRef]
  20. Langley, R.G.; Elewski, B.E.; Lebwohl, M.; Reich, K.; Griffiths, C.E.M.; Papp, K.; Puig, L.; Nakagawa, H.; Spelman, L.; Sigurgeirsson, B.; et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N. Engl. J. Med. 2014, 371, 326–338. [Google Scholar] [CrossRef] [Green Version]
  21. Keijsers, R.R.M.C.; Joosten, I.; van Erp, P.E.J.; Koenen, H.J.P.M.; van de Kerkhof, P.C.M. Cellular sources of IL-17 in psoriasis: A paradigm shift? Exp. Dermatol. 2014, 23, 799–803. [Google Scholar] [CrossRef] [PubMed]
  22. Hirota, K.; Ahlfors, H.; Duarte, J.H.; Stockinger, B. Regulation and function of innate and adaptive interleukin-17-producing cells. EMBO Rep. 2012, 13, 113–120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Spits, H.; Artis, D.; Colonna, M.; Diefenbach, A.; Di Santo, J.P.; Eberl, G.; Koyasu, S.; Locksley, R.M.; McKenzie, A.N.J.; Mebius, R.E.; et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 2013, 13, 145–149. [Google Scholar] [CrossRef] [PubMed]
  24. Diefenbach, A.; Colonna, M.; Koyasu, S. Development, differentiation, and diversity of innate lymphoid cells. Immunity 2014, 41, 354–365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kim, C.H.; Hashimoto-Hill, S.; Kim, M. Migration and Tissue Tropism of Innate Lymphoid Cells. Trends Immunol. 2016, 37, 68–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Vivier, E.; Artis, D.; Colonna, M.; Diefenbach, A.; Di Santo, J.P.; Eberl, G.; Koyasu, S.; Locksley, R.M.; McKenzie, A.N.J.; Mebius, R.E.; et al. Innate Lymphoid Cells: 10 Years On. Cell 2018, 174, 1054–1066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Brüggen, M.-C.; Bauer, W.M.; Reininger, B.; Clim, E.; Captarencu, C.; Steiner, G.E.; Brunner, P.M.; Meier, B.; French, L.E.; Stingl, G. In Situ Mapping of Innate Lymphoid Cells in Human Skin: Evidence for Remarkable Differences between Normal and Inflamed Skin. J. Investig. Dermatol. 2016, 136, 2396–2405. [Google Scholar] [CrossRef] [Green Version]
  28. Teunissen, M.B.M.; Munneke, J.M.; Bernink, J.H.; Spuls, P.I.; Res, P.C.M.; Te Velde, A.; Cheuk, S.; Brouwer, M.W.D.; Menting, S.P.; Eidsmo, L.; et al. Composition of innate lymphoid cell subsets in the human skin: Enrichment of NCR + ILC3 in lesional skin and blood of psoriasis patients. J. Investig. Dermatol. 2014, 134, 2351–2360. [Google Scholar] [CrossRef] [Green Version]
  29. Villanova, F.; Flutter, B.; Tosi, I.; Grys, K.; Sreeneebus, H.; Perera, G.K.; Chapman, A.; Smith, C.H.; Di Meglio, P.; Nestle, F.O. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J. Investig. Dermatol. 2014, 134, 984–991. [Google Scholar] [CrossRef] [Green Version]
  30. Boniface, K.; Bernard, F.-X.; Garcia, M.; Gurney, A.L.; Lecron, J.-C.; Morel, F. IL-22 Inhibits Epidermal Differentiation and Induces Proinflammatory Gene Expression and Migration of Human Keratinocytes. J. Immunol. 2005, 174, 3695–3702. [Google Scholar] [CrossRef] [Green Version]
  31. Lee, E.; Trepicchio, W.L.; Oestreicher, J.L.; Pittman, D.; Wang, F.; Chamian, F.; Dhodapkar, M.; Krueger, J.G. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 2004, 199, 125–130. [Google Scholar] [CrossRef] [PubMed]
  32. Keren, A.; Shemer, A.; Ginzburg, A.; Ullmann, Y.; Schrum, A.G.; Paus, R.; Gilhar, A. Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin. J. Allergy Clin. Immunol. 2018, 142, 305–308.e6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Dyring-Andersen, B.; Geisler, C.; Agerbeck, C.; Lauritsen, J.P.H.; Gúdjonsdottir, S.D.; Skov, L.; Bonefeld, C.M. Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br. J. Dermatol. 2014, 170, 609–616. [Google Scholar] [CrossRef] [PubMed]
  34. Van der Fits, L.; Mourits, S.; Voerman, J.S.A.; Kant, M.; Boon, L.; Laman, J.D.; Cornelissen, F.; Mus, A.-M.; Florencia, E.; Prens, E.P.; et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 2009, 182, 5836–5845. [Google Scholar] [CrossRef] [PubMed]
  35. Pantelyushin, S.; Haak, S.; Ingold, B.; Kulig, P.; Heppner, F.L.; Navarini, A.A.; Becher, B. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J. Clin. Investig. 2012, 122, 2252–2256. [Google Scholar] [CrossRef] [Green Version]
  36. Aparicio-Domingo, P.; Cupedo, T. Rorγt+ innate lymphoid cells in intestinal homeostasis and immunity. J. Innate Immun. 2011, 3, 577–584. [Google Scholar] [CrossRef]
  37. Zheng, Y.; Danilenko, D.M.; Valdez, P.; Kasman, I.; Eastham-Anderson, J.; Wu, J.; Ouyang, W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445, 648–651. [Google Scholar] [CrossRef]
  38. Hedrick, M.N.; Lonsdorf, A.S.; Shirakawa, A.-K.; Richard Lee, C.-C.; Liao, F.; Singh, S.P.; Zhang, H.H.; Grinberg, A.; Love, P.E.; Hwang, S.T.; et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J. Clin. Investig. 2009, 119, 2317–2329. [Google Scholar] [CrossRef] [Green Version]
  39. Girardi, M. Immunosurveillance and immunoregulation by γδ T cells. J. Investig. Dermatol. 2006, 126, 25–31. [Google Scholar] [CrossRef] [Green Version]
  40. Raulet, D.H. The structure, function, and molecular genetics of the gamma/delta T cell receptor. Annu. Rev. Immunol. 1989, 7, 175–207. [Google Scholar] [CrossRef]
  41. Bonneville, M.; O’Brien, R.L.; Born, W.K. γ δ T cell effector functions: A blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 2010, 10, 467–478. [Google Scholar] [CrossRef] [PubMed]
  42. Witherden, D.A.; Johnson, M.D.; Havran, W.L. Coreceptors and their ligands in epithelial γδ T cell biology. Front. Immunol. 2018, 9, 5–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Gao, Y.; Yang, W.; Pan, M.; Scully, E.; Girardi, M.; Augenlicht, L.H.; Craft, J.; Yin, Z. γδ T cells provide an early source of interferon γ in tumor immunity. J. Exp. Med. 2003, 198, 433–442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Workalemahu, G.; Foerster, M.; Kroegel, C.; Braun, R.K. Human γδ-T Lymphocytes Express and Synthesize Connective Tissue Growth Factor: Effect of IL-15 and TGF-β1 and Comparison with αβ-T Lymphocytes. J. Immunol. 2003, 170, 153–157. [Google Scholar] [CrossRef] [Green Version]
  45. Ebert, L.M.; Meuter, S.; Moser, B. Homing and function of human skin gammadelta T cells and NK cells: Relevance for tumor surveillance. J. Immunol. 2006, 176, 4331–4336. [Google Scholar] [CrossRef]
  46. Cordova, A.; Toia, F.; La Mendola, C.; Orlando, V.; Meraviglia, S.; Rinaldi, G.; Todaro, M.; Cicero, G.; Zichichi, L.; Donni, P.L.; et al. Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas. PLoS ONE 2012, 7, e49878. [Google Scholar] [CrossRef] [Green Version]
  47. Toulon, A.; Breton, L.; Taylor, K.R.; Tenenhaus, M.; Bhavsar, D.; Lanigan, C.; Rudolph, R.; Jameson, J.; Havran, W.L. A role for human skin-resident T cells in wound healing. J. Exp. Med. 2009, 206, 743–750. [Google Scholar] [CrossRef] [Green Version]
  48. Cruz, M.S.; Diamond, A.; Russell, A.; Jameson, J.M. Human αβ and γδ T Cells in Skin Immunity and Disease. Front. Immunol. 2018, 9, 1304. [Google Scholar] [CrossRef]
  49. Cai, Y.; Shen, X.; Ding, C.; Qi, C.; Li, K.; Li, X.; Jala, V.R.; Zhang, H.; Wang, T.; Zheng, J.; et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 2011, 35, 596–610. [Google Scholar] [CrossRef] [Green Version]
  50. Ramírez-Valle, F.; Gray, E.E.; Cyster, J.G. Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses. Proc. Natl. Acad. Sci. USA 2015, 112, 8046–8051. [Google Scholar] [CrossRef] [Green Version]
  51. Cai, Y.; Xue, F.; Quan, C.; Qu, M.; Liu, N.; Zhang, Y.; Fleming, C.; Hu, X.; Zhang, H.-G.; Weichselbaum, R.; et al. A Critical Role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. J. Investig. Dermatol. 2019, 139, 146–156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Laggner, U.; Di Meglio, P.; Perera, G.K.; Hundhausen, C.; Lacy, K.E.; Ali, N.; Smith, C.H.; Hayday, A.C.; Nickoloff, B.J.; Nestle, F.O. Identification of a Novel Proinflammatory Human Skin-Homing Vγ9Vδ2 T Cell Subset with a Potential Role in Psoriasis. J. Immunol. 2011, 187, 2783–2793. [Google Scholar] [CrossRef] [PubMed]
  53. Matos, T.R.; O’Malley, J.T.; Lowry, E.L.; Hamm, D.; Kirsch, I.R.; Robins, H.S.; Kupper, T.S.; Krueger, J.G.; Clark, R.A. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones. J. Clin. Investig. 2017, 127, 4031–4041. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Sumaria, N.; Roediger, B.; Ng, L.G.; Qin, J.; Pinto, R.; Cavanagh, L.L.; Shklovskaya, E.; Barbara, B.F.; Triccas, J.A.; Weninger, W. Cutaneous immunosurveillance by self-renewing dermal γδ T cells. J. Exp. Med. 2011, 208, 505–518. [Google Scholar] [CrossRef] [Green Version]
  55. Gentek, R.; Ghigo, C.; Hoeffel, G.; Jorquera, A.; Msallam, R.; Wienert, S.; Klauschen, F.; Ginhoux, F.; Bajénoff, M. Epidermal γδ T cells originate from yolk sac hematopoiesis and clonally self-renew in the adult. J. Exp. Med. 2018, 215, 2994–3005. [Google Scholar] [CrossRef] [Green Version]
  56. Cai, Y.; Xue, F.; Fleming, C.; Yang, J.; Ding, C.; Ma, Y.; Liu, M.; Zhang, H.; Zheng, J.; Xiong, N.; et al. Differential developmental requirement and peripheral regulation for dermal Vγ4 and Vγ6T17 cells in health and inflammation. Nat. Commun. 2014. [Google Scholar] [CrossRef]
  57. Gray, E.E.; Suzuki, K.; Cyster, J.G. Cutting edge: Identification of a motile IL-17-producing gammadelta T cell population in the dermis. J. Immunol. 2011, 186, 6091–6095. [Google Scholar] [CrossRef] [Green Version]
  58. Mabuchi, T.; Takekoshi, T.; Hwang, S.T. Epidermal CCR6+ γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J. Immunol. 2011, 187, 5026–5031. [Google Scholar] [CrossRef] [Green Version]
  59. Patel, U.; Mark, N.M.; Machler, B.C.; Levine, V.J. Imiquimod 5% cream induced psoriasis: A case report, summary of the literature and mechanism. Br. J. Dermatol. 2011, 164, 670–672. [Google Scholar] [CrossRef]
  60. Slauenwhite, D.; Johnston, B. Regulation of NKT cell localization in homeostasis and infection. Front. Immunol. 2015, 6. [Google Scholar] [CrossRef] [Green Version]
  61. Brennan, P.J.; Brigl, M.; Brenner, M.B. Invariant natural killer T cells: An innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 2013, 13, 101–117. [Google Scholar] [CrossRef] [PubMed]
  62. Yip, K.H.; Papadopoulos, M.; Pant, H.; Tumes, D.J. The role of invariant T cells in inflammation of the skin and airways. Semin. Immunopathol. 2019, 41, 401–410. [Google Scholar] [CrossRef] [PubMed]
  63. Lee, Y.J.; Wang, H.; Starrett, G.J.; Phuong, V.; Jameson, S.C.; Hogquist, K.A. Tissue-Specific Distribution of iNKT Cells Impacts Their Cytokine Response. Immunity 2015, 43, 566–578. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Cortesi, F.; Delfanti, G.; Casorati, G.; Dellabona, P. The pathophysiological relevance of the iNKT cell/mononuclear phagocyte crosstalk in tissues. Front. Immunol. 2018, 9, 1–11. [Google Scholar] [CrossRef] [Green Version]
  65. Bonish, B.; Jullien, D.; Dutronc, Y.; Huang, B.B.; Modlin, R.; Spada, F.M.; Porcelli, S.A.; Nickoloff, B.J. Overexpression of CD1d by Keratinocytes in Psoriasis and CD1d-Dependent IFN-γ Production by NK-T Cells. J. Immunol. 2000, 165, 4076–4085. [Google Scholar] [CrossRef] [Green Version]
  66. Vissers, W.H.P.M.; Berends, M.; Muys, L.; van Erp, P.E.J.; de Jong, E.M.G.J.; van de Kerkhof, P.C.M. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp. Dermatol. 2004, 13, 106–112. [Google Scholar] [CrossRef]
  67. Bovenschen, H.J.; Gerritsen, W.J.; Van Rens, D.W.A.; Seyger, M.M.B.; De Jong, E.M.G.J.; Van De Kerkhof, P.C.M. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. Arch. Dermatol. Res. 2007, 298, 457–463. [Google Scholar] [CrossRef]
  68. Chan, W.L.; Pejnovic, N.; Liew, T.V.; Lee, C.A.; Groves, R.; Hamilton, H. NKT cell subsets in infection and inflammation. Immunol. Lett. 2003, 85, 159–163. [Google Scholar] [CrossRef]
  69. Van Der Vliet, H.J.J.; Von Blomberg, B.M.E.; Nishi, N.; Reijm, M.; Voskuyl, A.E.; Van Bodegraven, A.A.; Polman, C.H.; Rustemeyer, T.; Lips, P.; Van Den Eertwegh, A.J.M.; et al. Circulating Vα24+ Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 2001, 100, 144–148. [Google Scholar] [CrossRef]
  70. Nickoloff, B.J.; Wrone-Smith, T.; Bonish, B.; Porcelli, S.A. Response of Murine and Normal Human Skin to Injection of Allogeneic Blood-Derived Psoriatic Immunocytes. Arch. Dermatol. 1999, 135, 546–552. [Google Scholar] [CrossRef] [Green Version]
  71. Gilhar, A.; Ullmann, Y.; Kerner, H.; Assy, B.; Shalaginov, R.; Serafimovich, S.; Kalish, R.S. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: Induction of psoriasis by cells with natural killer receptors. J. Investig. Dermatol. 2002, 119, 384–391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Nickoloff, B.J.; Bonish, B.; Huang, B.B.; Porcelli, S.A. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J. Dermatol. Sci. 2000, 24, 212–225. [Google Scholar] [CrossRef]
  73. Coquet, J.M.; Chakravarti, S.; Kyparissoudis, K.; McNab, F.W.; Pitt, L.A.; McKenzie, B.S.; Berzins, S.P.; Smyth, M.J.; Godfrey, D.I. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc. Natl. Acad. Sci. USA 2008, 105, 11287–11292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Doisne, J.-M.; Soulard, V.; Bécourt, C.; Amniai, L.; Henrot, P.; Havenar-Daughton, C.; Blanchet, C.; Zitvogel, L.; Ryffel, B.; Cavaillon, J.-M.; et al. Cutting edge: Crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1- invariant NKT cells to bacteria. J. Immunol. 2011, 186, 662–666. [Google Scholar] [CrossRef] [Green Version]
  75. Doisne, J.-M.; Becourt, C.; Amniai, L.; Duarte, N.; Le Luduec, J.-B.; Eberl, G.; Benlagha, K. Skin and Peripheral Lymph Node Invariant NKT Cells Are Mainly Retinoic Acid Receptor-Related Orphan Receptor γt + and Respond Preferentially under Inflammatory Conditions. J. Immunol. 2009, 183, 2142–2149. [Google Scholar] [CrossRef] [Green Version]
  76. Webster, K.E.; Kim, H.-O.; Kyparissoudis, K.; Corpuz, T.M.; Pinget, G.V.; Uldrich, A.P.; Brink, R.; Belz, G.T.; Cho, J.-H.; Godfrey, D.I.; et al. IL-17-producing NKT cells depend exclusively on IL-7 for homeostasis and survival. Mucosal Immunol. 2014, 7, 1058–1067. [Google Scholar] [CrossRef] [Green Version]
  77. Milosavljevic, N.; Gazdic, M.; Simovic Markovic, B.; Arsenijevic, A.; Nurkovic, J.; Dolicanin, Z.; Djonov, V.; Lukic, M.L.; Volarevic, V. Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells. Liver Transpl. 2017, 23, 1040–1050. [Google Scholar] [CrossRef] [Green Version]
  78. Bagchi, S.; He, Y.; Zhang, H.; Cao, L.; Van Rhijn, I.; Moody, D.B.; Gudjonsson, J.E.; Wang, C.R. CD1b-autoreactive T cells contribute to hyperlipidemia-induced skin inflammation in mice. J. Clin. Investig. 2017, 127, 2339–2352. [Google Scholar] [CrossRef]
  79. Caligiuri, M.A. Human natural killer cells. Blood 2008, 112, 461–469. [Google Scholar] [CrossRef]
  80. Biron, C.A.; Nguyen, K.B.; Pien, G.C.; Cousens, L.P.; Salazar-Mather, T.P. NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines. Annu. Rev. Immunol. 1999, 17, 189–220. [Google Scholar] [CrossRef]
  81. Moretta, L.; Bottino, C.; Pende, D.; Mingari, M.C.; Biassoni, R.; Moretta, A. Human natural killer cells: Their origin, receptors and function. Eur. J. Immunol. 2002, 32, 1205–1211. [Google Scholar] [CrossRef]
  82. Belizário, J.E.; Neyra, J.M.; Setúbal Destro Rodrigues, M.F. When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection. Innate Immun. 2018, 24, 452–465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Carrillo-Bustamante, P.; Keşmir, C.; de Boer, R.J. The evolution of natural killer cell receptors. Immunogenetics 2016, 68, 3–18. [Google Scholar] [CrossRef] [Green Version]
  84. Trowsdale, J. Genetic and Functional Relationships between MHC and NK Receptor Genes HLA class I and NK receptors are encoded within. Immunity 2001, 15, 363–374. [Google Scholar] [CrossRef] [Green Version]
  85. Barten, R.; Torkar, M.; Haude, A.; Trowsdale, J.; Wilson, M.J. Divergent and convergent evolution of NK-cell receptors. Trends Immunol. 2001, 22, 52–57. [Google Scholar] [CrossRef]
  86. Vivier, E.; Nunès, J.A.; Vély, F. Natural killer cell signaling pathways. Science 2004, 306, 1517–1519. [Google Scholar] [CrossRef] [PubMed]
  87. Borrego, F.; Masilamani, M.; Marusina, A.I.; Tang, X.; Coligan, J.E. The CD94/NKG2 family of receptors: From molecules and cells to clinical relevance. Immunol. Res. 2006, 35, 263–277. [Google Scholar] [CrossRef]
  88. Cooper, M.A.; Fehniger, T.A.; Caligiuri, M.A. The biology of human natural killer-cell subsets. Trends Immunol. 2001, 22, 633–640. [Google Scholar] [CrossRef]
  89. Hudspeth, K.; Donadon, M.; Cimino, M.; Pontarini, E.; Tentorio, P.; Preti, M.; Hong, M.; Bertoletti, A.; Bicciato, S.; Invernizzi, P.; et al. Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J. Autoimmun. 2016, 66, 40–50. [Google Scholar] [CrossRef] [Green Version]
  90. Di Santo, J.P. Functionally distinct NK-cell subsets: Developmental origins and biological implications. Eur. J. Immunol. 2008, 38, 2948–2951. [Google Scholar] [CrossRef]
  91. Peng, H.; Tian, Z. Diversity of tissue-resident NK cells. Semin. Immunol. 2017, 31, 3–10. [Google Scholar] [CrossRef]
  92. Cameron, A.; Kirby, B.; Fei, W.; Griffiths, C.E.M. Natural killer and natural killer-T cells in psoriasis. Arch. Dermatol. Res. 2002, 294, 363–369. [Google Scholar] [CrossRef]
  93. Vissers, W.H.P.M.; Arndtz, C.H.M.; Muys, L.; Van Erp, P.E.J.; de Jong, E.M.G.; van de Kerkhof, P.C.M. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br. J. Dermatol. 2004, 150, 852–859. [Google Scholar] [CrossRef] [PubMed]
  94. Ottaviani, C.; Nasorri, F.; Bedini, C.; de Pità, O.; Girolomoni, G.; Cavani, A. CD56brightCD16- NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur. J. Immunol. 2006, 36, 118–128. [Google Scholar] [CrossRef] [PubMed]
  95. Cardili, R.N.; Alves, T.G.; Freitas, J.C.O.C.; Soares, C.P.; Mendes-Junior, C.T.; Soares, E.G.; Donadi, E.A.; Silva-Souza, C. Expression of human leucocyte antigen-G primarily targets affected skin of patients with psoriasis. Br. J. Dermatol. 2010, 163, 769–775. [Google Scholar] [CrossRef] [PubMed]
  96. Rajagopalan, S.; Long, E.O. KIR2DL4 (CD158d): An activation receptor for HLA-G. Front. Immunol. 2012, 3, 258. [Google Scholar] [CrossRef] [Green Version]
  97. Chowdhury, A.C.; Chaurasia, S.; Mishra, S.K.; Aggarwal, A.; Misra, R. IL-17 and IFN-γ producing NK and γδ-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis. Clin. Immunol. 2017, 183, 207–212. [Google Scholar] [CrossRef]
  98. Cella, M.; Fuchs, A.; Vermi, W.; Facchetti, F.; Otero, K.; Lennerz, J.K.M.; Doherty, J.M.; Mills, J.C.; Colonna, M. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457, 722–725. [Google Scholar] [CrossRef]
  99. Cameron, A.L.; Kirby, B.; Griffiths, C.E.M. Circulating natural killer cells in psoriasis. Br. J. Dermatol. 2003, 149, 160–164. [Google Scholar] [CrossRef]
  100. Gambichler, T.; Zhang, Y.; Höxtermann, S.; Kreuter, A. Natural killer cells and B lymphocytes in peripheral blood of patients with psoriasis. Br. J. Dermatol. 2013, 168, 894–896. [Google Scholar] [CrossRef]
  101. Dunphy, S.E.; Sweeney, C.M.; Kelly, G.; Tobin, A.M.; Kirby, B.; Gardiner, C.M. Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production. Clin. Immunol. 2017, 177, 43–49. [Google Scholar] [CrossRef] [PubMed]
  102. Vičić, M.; Kaštelan, M.; Sotošek Tokmadžić, V.; Prpić Massari, L. Systemic and Local Increase of Granulysin Expression in Cytotoxic Lymphocytes in Severe Psoriasis. Acta Derm. Venereol. 2019, 99, 1136–1142. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Ermis, E.; Celik, S.K.; Solak, N.; Genc, G.C.; Dursun, A. The role of GNLY gene polymorphisms in psoriasis pathogenesis. An. Bras. Dermatol. 2019, 94, 198–203. [Google Scholar] [CrossRef]
  104. Holm, S.J.; Sakuraba, K.; Mallbris, L.; Wolk, K.; Ståhle, M.; Sánchez, F.O. Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J. Investig. Dermatol. 2005, 125, 721–730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Chen, H.; Hayashi, G.; Lai, O.Y.; Dilthey, A.; Kuebler, P.J.; Wong, T.V.; Martin, M.P.; Fernandez Vina, M.A.; McVean, G.; Wabl, M.; et al. Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. PLoS Genet. 2012, 8, e1002514. [Google Scholar] [CrossRef] [PubMed]
  106. Zeng, X.; Chen, H.; Gupta, R.; Paz-Altschul, O.; Bowcock, A.M.; Liao, W. Deletion of the activating NKG2C receptor and a functional polymorphism in its ligand HLA-E in psoriasis susceptibility. Exp. Dermatol. 2013, 22, 679–681. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  107. Uhrberg, M. The KIR gene family: Life in the fast lane of evolution. Eur. J. Immunol. 2005, 35, 10–15. [Google Scholar] [CrossRef]
  108. Surcel, M.; Huică, R.-I.; Munteanu, A.; Isvoranu, G.; Pîrvu, I.; Ciotaru, D.; Constantin, C.; Bratu, O.; Căruntu, C.; Neagu, M.; et al. Phenotypic changes of lymphocyte populations in psoriasiform dermatitis animal model. Exp. Ther. Med. 2018, 17, 1030–1038. [Google Scholar] [CrossRef] [Green Version]
  109. Surcel, M.; Munteanu, A.N.; Huică, R.-I.; Isvoranu, G.; Pîrvu, I.R.; Constantin, C.; Bratu, O.; Căruntu, C.; Zaharescu, I.; Sima, L.; et al. Reinforcing involvement of NK cells in psoriasiform dermatitis animal model. Exp. Ther. Med. 2019, 18, 4956–4966. [Google Scholar] [CrossRef] [Green Version]
Ijms 21 06604 g001 550
Figure 1. Role of group 3 innate lymphoid cells (ILC3s) in psoriatic lesions. In healthy skin, a few natural cytotoxicity receptor-negative (NCR–) ILC3s are present in the dermis. Contrastingly, NCR+ ILC3s are increased in psoriatic lesions. NCR– ILC3s may convert to NCR+ ILC3s in response to cytokines secreted by keratinocytes and dendritic cells. NCR+ ILC3s produce IL-22, rather than IL-17, in response to IL-23 secreted by dendritic cells and IL-1β secreted by keratinocytes. IL-22, and potentially IL-17, secreted by NCR+ ILC3s contribute to the pathogenesis of psoriasis.
Figure 1. Role of group 3 innate lymphoid cells (ILC3s) in psoriatic lesions. In healthy skin, a few natural cytotoxicity receptor-negative (NCR–) ILC3s are present in the dermis. Contrastingly, NCR+ ILC3s are increased in psoriatic lesions. NCR– ILC3s may convert to NCR+ ILC3s in response to cytokines secreted by keratinocytes and dendritic cells. NCR+ ILC3s produce IL-22, rather than IL-17, in response to IL-23 secreted by dendritic cells and IL-1β secreted by keratinocytes. IL-22, and potentially IL-17, secreted by NCR+ ILC3s contribute to the pathogenesis of psoriasis.
Ijms 21 06604 g001
Ijms 21 06604 g002 550
Figure 2. Role of γδ T cells in mouse models of psoriasis. Vγ4 and Vγ6 γδ T cells are present in normal mouse skin. Dermal Vγ4 γδ T cells increase in psoriasis-like dermatitis lesions generated by imiquimod application. Vγ4 and Vγ6 γδ T cells, rather than αβ T cells, produce IL-17. C-C motif chemokine receptor 6-positive (CCR6+) γδ T cells lacking Vγ5 are recruited from the peripheral blood into the epidermis and produce IL-22 once recruited. γδ T cells contribute to the development of psoriasis via both IL-17 and IL-22.
Figure 2. Role of γδ T cells in mouse models of psoriasis. Vγ4 and Vγ6 γδ T cells are present in normal mouse skin. Dermal Vγ4 γδ T cells increase in psoriasis-like dermatitis lesions generated by imiquimod application. Vγ4 and Vγ6 γδ T cells, rather than αβ T cells, produce IL-17. C-C motif chemokine receptor 6-positive (CCR6+) γδ T cells lacking Vγ5 are recruited from the peripheral blood into the epidermis and produce IL-22 once recruited. γδ T cells contribute to the development of psoriasis via both IL-17 and IL-22.
Ijms 21 06604 g002
Ijms 21 06604 g003 550
Figure 3. Role of natural killer T (NKT) cells in psoriasis. In psoriatic lesions, CD1d is widely expressed on keratinocytes in all layers of the epidermis. Keratinocyte CD1d expression is induced by interferon-γ (IFN-γ), which is produced by CD94+/CD161+ NKT cells. The interaction between NKT cells and CD1d expressed on keratinocytes could contribute to psoriasis.
Figure 3. Role of natural killer T (NKT) cells in psoriasis. In psoriatic lesions, CD1d is widely expressed on keratinocytes in all layers of the epidermis. Keratinocyte CD1d expression is induced by interferon-γ (IFN-γ), which is produced by CD94+/CD161+ NKT cells. The interaction between NKT cells and CD1d expressed on keratinocytes could contribute to psoriasis.
Ijms 21 06604 g003
Ijms 21 06604 g004 550
Figure 4. Role of NK cells in psoriatic lesions. In healthy skin, CD56bright NK cells are localized to the dermis, and CD56dim NK cells are present predominately in the peripheral blood. In psoriatic skin, CD56bright NK cells are increased and express the activation marker CD69. Keratinocyte HLA-G expression is increased in psoriatic lesions, which may induce NK cell IFN-γ and TNF-α production.
Figure 4. Role of NK cells in psoriatic lesions. In healthy skin, CD56bright NK cells are localized to the dermis, and CD56dim NK cells are present predominately in the peripheral blood. In psoriatic skin, CD56bright NK cells are increased and express the activation marker CD69. Keratinocyte HLA-G expression is increased in psoriatic lesions, which may induce NK cell IFN-γ and TNF-α production.
Ijms 21 06604 g004
Table
Table 1. The Profiles of Innate Immune Cells in the Healthy Condition and Psoriasis.
Table 1. The Profiles of Innate Immune Cells in the Healthy Condition and Psoriasis.
Cell Type TissueHealthy ConditionPsoriasis
ILC3NumberSkinPresenceIncrease
PBPresenceIncrease *
PhenotypeSkin, PBNCR-NCR+
Skin, PB IL-22 (+)
γδT cellNumberSkinPresenceIncrease
PBPresenceDecrease
PhenotypeSkin IL-17 (+), IL-22 (+)
NKT cellNumberSkinPresenceIncrease?
PBPresencePresence
PhenotypeSkin IFN-g (+)
NK cellNumberSkinPresenceIncrease
PBPresenceDecrease
PhenotypeSkinN.A.CD69+
Skin IFN-γ (+), TNF-α (+)
* The number of NCR+ ILC3s. N.A., not assessed; PB, peripheral blood.

Share and Cite

MDPI and ACS Style

Sato, Y.; Ogawa, E.; Okuyama, R. Role of Innate Immune Cells in Psoriasis. Int. J. Mol. Sci. 2020, 21, 6604. https://doi.org/10.3390/ijms21186604

AMA Style

Sato Y, Ogawa E, Okuyama R. Role of Innate Immune Cells in Psoriasis. International Journal of Molecular Sciences. 2020; 21(18):6604. https://doi.org/10.3390/ijms21186604

Chicago/Turabian Style

Sato, Yuki, Eisaku Ogawa, and Ryuhei Okuyama. 2020. "Role of Innate Immune Cells in Psoriasis" International Journal of Molecular Sciences 21, no. 18: 6604. https://doi.org/10.3390/ijms21186604

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop